Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Systemic amiloride inhibits experimentally induced neovascularization. Arch Ophthalmol 1990 Oct;108(10):1474-6

Date

10/11/1990

Pubmed ID

1699514

DOI

10.1001/archopht.1990.01070120122041

Scopus ID

2-s2.0-0025130655 (requires institutional sign-in at Scopus site)   51 Citations

Abstract

Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E1 pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.

Author List

Avery RL, Connor TB Jr, Farazdaghi M

Author

Thomas B. Connor MD Professor in the Ophthalmology and Visual Sciences department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Alprostadil
Amiloride
Animals
Cornea
Disease Models, Animal
Neovascularization, Pathologic
Photography
Rabbits